The most counter-intuitive recommendation in cancer care is also the most evidence-based. For a meaningful fraction of men diagnosed with prostate cancer, the right next step is not surgery, not radiation, not hormonal therapy. It is, structurally, a programme of careful watching — a strategy called active surveillance.
This is not "doing nothing." It is a defined medical protocol with a schedule, a set of triggers that escalate to treatment, and a body of long-term outcomes data that strongly supports it. For Gleason 6, organ-confined prostate cancer in men with at least a decade of life expectancy, active surveillance produces cancer-specific survival outcomes statistically indistinguishable from immediate definitive treatment — without the immediate side effects of surgery or radiation.
And yet, in many parts of India and globally, it is dramatically underused. The reasons are partly cultural ("if there's cancer, get it out"), partly structural (urology and oncology departments are organised around interventions), and partly informational (most patients have never heard of it as an option). This article is an attempt to fix the last one.
Why prostate cancer needs a different framework
Prostate cancer is unusual among cancers in that a substantial fraction of cases — possibly the majority — are biologically indolent. Autopsy studies of men who died of unrelated causes have consistently shown that microscopic prostate cancer is present in about thirty per cent of men in their fifties and sixty per cent of men in their eighties. Most of these cancers will never cause symptoms, never spread, and never matter to the person carrying them. They are, for practical purposes, an artifact of ageing rather than a disease.
The diagnostic problem is that prostate biopsies, especially when triggered by elevated PSA, can detect these biologically indolent cancers. The treatment problem is that historically, the response to any positive biopsy was definitive treatment — and definitive treatment for prostate cancer carries non-trivial side effects: urinary incontinence in five to ten per cent, erectile dysfunction in twenty to fifty per cent, bowel issues in some, and the recovery time and surgical risk associated with the procedure itself.
If you treat aggressively a cancer that was never going to harm the patient, you have caused harm without preventing harm. That asymmetry is the over-treatment problem in prostate cancer, and active surveillance is the response to it.
Who is a candidate
Active surveillance is appropriate for a specific risk profile, well-defined by the NCCN and EAU guidelines:
- Gleason score 6 (also called Grade Group 1) — the lowest-grade prostate cancer.
- Clinical stage T1c or T2a — confined to the prostate, not palpable as a large mass.
- PSA < 10 ng/mL, often with PSA density (PSA divided by prostate volume) < 0.15.
- Limited tumour volume on biopsy — typically fewer than 3 cores positive, with no core greater than 50% involvement.
- Life expectancy > 10 years — though active surveillance is appropriate at any age if the cancer is truly low-risk.
Men with Gleason 7 disease, especially Gleason 4+3, are generally not candidates — that biology has too much potential to progress to be safely watched. Some Gleason 3+4 patients with very low volume disease are candidates for active surveillance under newer expanded criteria, but this requires careful selection and an experienced multidisciplinary team.
What the protocol looks like
The standard active-surveillance protocol has three components, all aimed at catching disease progression before it becomes meaningful:
1. PSA every six months
Slow rises in PSA are normal with age and benign prostate enlargement. A persistent or accelerating rise — especially in the context of a stable prostate volume — suggests something has changed. PSA velocity and PSA doubling time are the metrics most often used. A PSA doubling time under three years on active surveillance is a trigger to investigate further.
2. Multi-parametric MRI annually
Prostate MRI has transformed active surveillance over the last decade. It can identify suspicious lesions that might warrant a targeted biopsy, and equally important, it can confirm that a known low-risk lesion is stable. Most active-surveillance protocols now include a baseline mpMRI and annual follow-up imaging.
3. Repeat biopsy if anything changes
If PSA accelerates, MRI shows new or growing lesions, or both, a repeat biopsy is performed. This is the primary mechanism by which Gleason 6 is "upgraded" to Gleason 7 — sometimes the original biopsy missed a higher-grade area, sometimes the cancer has actually progressed in biology. Either way, an upgrade to Gleason 7 is the trigger to convert from surveillance to definitive treatment.
Active surveillance is not 'doing nothing.' It is a defined protocol with a schedule, escalation triggers, and decades of outcomes data behind it.
What the long-term data shows
The largest active-surveillance cohorts — Toronto (Klotz), Johns Hopkins (Tosoian), Royal Marsden, and the international ProtecT trial — now have follow-up exceeding fifteen years. The headline results are remarkably consistent:
- Cancer-specific mortality at fifteen years on active surveillance: approximately 1-2%.
- Approximately 30-50% of men on active surveillance eventually convert to definitive treatment, usually within the first 5-7 years.
- Of those who convert, the cancer-specific outcomes after delayed treatment are similar to those who chose immediate treatment.
- Quality of life on active surveillance is significantly better in the first 5-10 years compared to immediate treatment, particularly for urinary, sexual, and bowel function.
Read together: active surveillance gives you the option of avoiding treatment-related morbidity for as long as the cancer remains indolent, while preserving the option of effective treatment if and when the biology shifts. It is the textbook case of "delay treatment without losing the cure window."
The psychological challenge
Active surveillance is not always easy to live with. Many men describe the period after diagnosis as anxious — there's a cancer in your body, and you're not removing it. Family members can find it harder to accept than the patient does. The decision to defer treatment requires comfort with uncertainty, a trustworthy surveillance plan, and a doctor who can answer questions calmly when PSA goes up by 0.5 between visits.
For men who can't tolerate the uncertainty, immediate treatment is a defensible choice. The point of active surveillance isn't to push everyone toward delay — it's to make delay an informed option for those who would otherwise commit to treatment they don't medically need. A second opinion is almost always worth getting before committing to either path.
When to convert to treatment
The triggers to convert from surveillance to definitive treatment are well-defined:
- Upgrade to Gleason 7 or higher on repeat biopsy.
- Volume increase — significantly more cores positive, or higher percentage involvement of cores.
- PSA doubling time under 3 years, especially if combined with imaging changes.
- New or growing MRI-visible lesion.
- Patient preference — if living with the diagnosis becomes intolerable, that's a valid reason to convert.
Conversion is not a failure. It is the protocol working as designed. Most men who convert do so within the first seven years, and the outcomes after delayed treatment are comparable to those of immediate treatment.
The summary
For Gleason 6, organ-confined prostate cancer with low PSA density and limited tumour volume, active surveillance is a defensible — and often the preferred — first choice. The protocol is not "doing nothing": it is a structured plan of PSA every six months, MRI annually, and repeat biopsy on triggers, with the option to convert to definitive treatment if the biology changes. The long-term cancer-specific survival data is excellent, the side-effect burden is dramatically lower, and the option for definitive treatment is preserved if needed. For the right patient, it is the most evidence-based option in oncology that most patients have never been offered. See the prostate cancer treatment page for the full menu of options.